Opaleye Management’s Travere Therapeutics TVTX Stock Holding History

Opaleye Management’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-205,000	Closed	-$4.64M	–	52
2019 Q1	$4.64M	Buy	+205,000	New	+$4.53M	1.28%	33
2016 Q2	–	Sell	-150,000	Closed	-$2.05M	–	56
2016 Q1	$2.05M	Sell	150,000 -195,000	-57%	-$2.96M	1.28%	31
2015 Q4	$6.66M	Sell	345,000 -25,000	-7%	-$499K	2.78%	15
2015 Q3	$7.5M	Sell	370,000 -90,000	-20%	-$2.67M	3.69%	9
2015 Q2	$15.2M	Sell	460,000 -40,000	-8%	-$1.1M	6.07%	3
2015 Q1	$12M	Sell	500,000 -420,000	-46%	-$6.4M	5.56%	4
2014 Q4	$11.3M	Sell	920,000 -80,000	-8%	-$828K	5.69%	4
2014 Q3	$9.02M	Sell	1,000,000 -216,400	-18%	-$2.55M	7.03%	3
2014 Q2	$14.3M	Buy	1,216,400 +63,170	+5%	+$856K	12.31%	2
2014 Q1	$24.4M	Buy	+1,153,230	New	+$17.7M	18.06%	1

Other funds holding TVTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Opaleye Management's TVTX Position: Q2 2019 in Review

Opaleye Management sold out of Travere Therapeutics (TVTX) in Q2 2019, closing a stake of 205,000 shares — an estimated $4.64M sold.

Opaleye Management first reported a position in TVTX in Q1 2014 and held it in 10 quarters. The position peaked at $24.4M in Q1 2014. 122 funds tracked by Wall St. Rank hold TVTX as of Q2 2019.

Opaleye Management reported no remaining Travere Therapeutics position as of Q2 2019 after selling out during the quarter.
Opaleye Management sold 205,000 Travere Therapeutics shares in Q2 2019, an estimated $4.64M.
Opaleye Management first reported a position in Travere Therapeutics in Q1 2014 and held it in 10 quarters.
Opaleye Management's Travere Therapeutics position peaked at $24.4M in Q1 2014.
122 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2019.

Based on Opaleye Management's 13F filing for Q2 2019, filed 14 Aug 2019.